Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | February 27, 2015 | March 03, 2015 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2015 · Filed March 03, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 12,129 |
Reported balance
After 2015-02-27 transaction · row 1
1 source rowRow 1 · 2015-02-27 · Grant · Acquired 4,462 · Balance 12,129 F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2015 Filed Mar 3, 2015 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-004048 · edgar.xml · nonDerivative · entry 1 DeVos Georges H. · CIK 0001580246 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,129 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 117,878 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003355 · edgar.xml · derivative · entry 1 DeVos Georges H. · CIK 0001580246 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,878 Underlying: Common shares · 117,878 shares Expires 2025-02-19 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 39,293 on 2/20/16, 39,292 on 2/20/17, and 39,293 on 2/20/18. Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 7,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-011326 · edgar.xml · nonDerivative · entry 1 DeVos Georges H. · CIK 0001580246 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,667 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 81,940 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003624 · edgar.xml · derivative · entry 1 DeVos Georges H. · CIK 0001580246 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,940 Underlying: Common shares · 81,940 shares Expires 2024-02-20 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,314 on 2/21/2015, 27,313 on 2/21/2016, and 27,313 on 2/21/2017. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 21:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 119,700 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001179110-13-011552 · edgar.xml · derivative · entry 1 DeVos Georges H. · CIK 0001580246 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,700 Underlying: Common shares · 119,700 shares Expires 2023-06-30 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 39,900 on 7/1/2014, 39,900 on 7/1/2015, and 39,900 on 7/1/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.